Clinical epidemiology of Epstein-Barr virus-associated Lymphoproliferative Disorders (EBV-LPDs) in hospitalized children: A six-year multi-institutional study in China.

Publisher: BioMed Central Country of Publication: England NLM ID: 101510759 Publication Model: Electronic Cited Medium: Internet ISSN: 1824-7288 (Electronic) Linking ISSN: 17208424 NLM ISO Abbreviation: Ital J Pediatr Subsets: MEDLINE

Original Publication: London : BioMed Central

Lymphoproliferative Disorders*/epidemiology ; Lymphoproliferative Disorders*/virology ; Epstein-Barr Virus Infections*/epidemiology ; Epstein-Barr Virus Infections*/complications; Humans ; China/epidemiology ; Child ; Male ; Female ; Child, Preschool ; Infant ; Adolescent ; Retrospective Studies ; Infant, Newborn ; Hospitalization/statistics & numerical data ; Herpesvirus 4, Human/isolation & purification ; Child, Hospitalized

Background: Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPDs) are a group of disorders involving lymphoid tissues or lymphocytes. The epidemiology and economic burden of hospitalized children with EBV-LPDs in China have not been well studied. This study aimed to reveal the epidemic characteristics and disease burden of EBV-LPDs among the Chinese hospitalized children, providing strategies for the prevention and management.
Methods: This study was based on the FUTang Updating medical REcords (FUTURE) database of China and collected the medical records from 27 tertiary children's hospitals between January 2016 and December 2021 in China, counting five types of EBV-LPDs, namely EBV-positive T-cell lymphoproliferative disease, NK/T cell lymphoma, extranodal NK/T-cell lymphoma (nasal type), systemic EBV-positive T-cell lymphoproliferative disease of childhood and posttransplant lymphoproliferative disorders. We conducted a retrospective syhthesis and analysis of the epidemiological characteristics, expenses, length of stay (LOS), as well as complications among hospitalized children diagnosed with five types of EBV-LPDs and compared parameters using appropriate statistical tests.
Results: The study described 153 children aged 0-18 years hospitalized with EBV-LPDs from 2016 to 2021 in the FUTURE database. The male-to-female ratio was 1.10:1, and more than half of the age distribution was in the 6-12 y group. Among EBV-LPDs cases, EBV ⁺ T-LPD accounted for the largest proportion (65.36%). Complications were presented in 93 children with EBV-LPDs, mainly hemophagocytic lymphohistiocytosis (HLH). The median LOS of NKTL was 26.5 days [interquartile range (IQR) = 3-42], which was the longest among EBV-LPDs. The median hospitalization cost of PTLD was 10 785.74 United States dollars (IQR = 7 329.38-16 531.18), which was the heaviest among EBV-LPDs.
Conclusions: Compared with the total number of hospitalized children in China during the same period and in the same age group, the proportion of EBV-LPD is very low. EBV-LPD can develop in all age groups, but it is more common in school-age children. Among 5 EBV-LPDs, the disease with the highest proportion is EBV ⁺ T-LPD. The overall disease burden of EBV-LPD was heavy, especially the economic burden. HLH was one of the most common complications, which could directly affect the burden of patients because of prolonged hospitalization. These data are taken from a very large database, illustrating the epidemiological and economic burden of EBV-LPDs hospitalized children in China, which enriched the existing epidemiological and disease burden content of EBV-LPDs.
(© 2024. The Author(s).)

Cell. 2022 Sep 29;185(20):3652-3670. (PMID: 36113467)
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):716-725. (PMID: 36709164)
Leukemia. 2021 Sep;35(9):2460-2468. (PMID: 34117356)
Front Pediatr. 2019 Jan 04;6:417. (PMID: 30662890)
Hemasphere. 2021 Jan 12;5(2):e523. (PMID: 33458595)
Rev Med Virol. 2022 Jul;32(4):e2328. (PMID: 35122349)
Curr Hematol Malig Rep. 2016 Dec;11(6):492-503. (PMID: 27995419)
Clin Lymphoma. 2003 Dec;4(3):161-8. (PMID: 14715098)
Semin Diagn Pathol. 2020 Jan;37(1):32-46. (PMID: 31889602)
Lancet. 2022 Sep 24;400(10357):1020-1032. (PMID: 36154677)
Br J Haematol. 2011 Jan;152(1):2. (PMID: 21197699)
Front Pediatr. 2019 Mar 15;7:71. (PMID: 30931288)
Hematology Am Soc Hematol Educ Program. 2015;2015:177-82. (PMID: 26637718)
Blood. 2013 Jun 20;121(25):4997-5005. (PMID: 23652805)
Int J Cancer. 2007 Jan 15;120(2):406-10. (PMID: 17066445)
Leuk Lymphoma. 2019 Jan;60(1):142-150. (PMID: 29966464)
Am J Transplant. 2011 May;11(5):888-95. (PMID: 21521464)
Curr Opin Hematol. 2014 Nov;21(6):476-81. (PMID: 25159713)
Am J Surg Pathol. 2020 Aug;44(8):1061-1072. (PMID: 32317607)
Annu Rev Pathol. 2018 Jan 24;13:27-49. (PMID: 28934563)
Leukemia. 2022 Jul;36(7):1720-1748. (PMID: 35732829)
Chin J Cancer Res. 2022 Oct 30;34(5):425-446. (PMID: 36398117)
Front Immunol. 2022 Apr 14;13:867918. (PMID: 35493498)
Korean J Pathol. 2013 Apr;47(2):137-47. (PMID: 23667373)
J Hematol Oncol. 2017 Apr 14;10(1):85. (PMID: 28410601)
Orphanet J Rare Dis. 2013 Jul 01;8:95. (PMID: 23816348)
Front Oncol. 2019 Mar 07;9:109. (PMID: 30899698)
Ann Hematol. 2016 Dec;95(12):2023-2031. (PMID: 27595760)
Hum Pathol. 2018 Sep;79:18-41. (PMID: 29885408)
Front Oncol. 2022 Apr 19;12:838817. (PMID: 35515118)
Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727)
Exp Mol Med. 2015 Jan 23;47:e133. (PMID: 25613730)
Virchows Arch. 2023 Jan;482(1):227-244. (PMID: 36216980)
Blood. 2022 Feb 17;139(7):983-994. (PMID: 34437680)

82002129 National Natural Science Foundation of China; 2024-4-1142 Capital's Funds for Health Improvement and Research; 202328 Beijing Hospitals Authority Innovation Studio of Young Staff Funding; BJMB0012022028010 2022 Scientific Research Project of Chronic Diseases Control and Health Education

Keywords: Children; EBV-LPD; Epidemiology; Epstein-Barr virus; Hospitalization

Date Created: 20240703 Date Completed: 20240703 Latest Revision: 20240711

20240711

PMC11218373

10.1186/s13052-024-01685-y

38956696